Division of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, 215-4 Gongneung-Dong, Nowon-Ku, Seoul, 139-706, South Korea.
Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon, South Korea.
BMC Cancer. 2018 Jul 5;18(1):716. doi: 10.1186/s12885-018-4600-6.
Although MASTL (microtubule-associated serine/threonine kinase-like) is a key mitotic kinase that regulates mitotic progression through the inactivation of tumor suppressor protein phosphatase 2A (PP2A), the antitumor mechanism of MASTL targeting in cancer cells is still unclear.
MASTL expression was evaluated by using breast cancer tissue microarrays and public cancer databases. The effects of MASTL depletion with siRNAs were evaluated in various breast cancer cells or normal cells. Various methods, including cell viability, cell cycle, soft agar, immunoblotting, immunofluorescence, PP2A activity, live image, and sphere forming assay, were used in this study.
This study showed the oncosuppressive mechanism of MASTL targeting that promotes mitotic catastrophe through PP2A activation selectively in breast cancer cells. MASTL expression was closely associated with tumor progression and poor prognosis in breast cancer. The depletion of MASTL reduced the oncogenic properties of breast cancer cells with high MASTL expression, but did not affect the viability of non-transformed normal cells with low MASTL expression. With regard to the underlying mechanism, we found that MASTL inhibition caused mitotic catastrophe through PP2A activation in breast cancer cells. Furthermore, MASTL depletion enhanced the radiosensitivity of breast cancer cells with increased PP2A activity. Notably, MASTL depletion dramatically reduced the formation of radioresistant breast cancer stem cells in response to irradiation.
Our data suggested that MASTL inhibition promoted mitotic catastrophe through PP2A activation, which led to the inhibition of cancer cell growth and a reversal of radioresistance in breast cancer cells.
尽管 MASTL(微管相关丝氨酸/苏氨酸激酶样)是一种关键的有丝分裂激酶,通过失活肿瘤抑制蛋白磷酸酶 2A(PP2A)来调节有丝分裂进程,但 MASTL 在癌细胞中的抗肿瘤机制仍不清楚。
使用乳腺癌组织微阵列和公共癌症数据库评估 MASTL 的表达。通过 siRNA 敲低 MASTL 在各种乳腺癌细胞或正常细胞中评估其作用。本研究采用了细胞活力、细胞周期、软琼脂、免疫印迹、免疫荧光、PP2A 活性、活细胞成像和球体形成测定等多种方法。
本研究揭示了 MASTL 靶向的抗肿瘤机制,即通过选择性激活 PP2A 在乳腺癌细胞中促进有丝分裂灾难。MASTL 的表达与乳腺癌的肿瘤进展和预后不良密切相关。MASTL 的敲低降低了高 MASTL 表达的乳腺癌细胞的致癌特性,但对低 MASTL 表达的非转化正常细胞的活力没有影响。在潜在机制方面,我们发现 MASTL 抑制通过 PP2A 激活导致乳腺癌细胞中的有丝分裂灾难。此外,MASTL 敲低增强了具有增加的 PP2A 活性的乳腺癌细胞对放射治疗的敏感性。值得注意的是,MASTL 敲低显著减少了对辐照的耐药性乳腺癌干细胞的形成。
我们的数据表明,MASTL 抑制通过 PP2A 激活促进有丝分裂灾难,从而抑制癌细胞生长并逆转乳腺癌细胞的放射抗性。